Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16306447
Shao Z, et al. (2006) c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ Res 98, 111-8 16306447
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S124-p - Akt1 (human)
Modsite: EMDFRsGsPsDNsGA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S124‑p, Akt1 iso2 (human): S62‑p, Akt1 (mouse): S124‑p, Akt1 (rat): S124‑p, Akt1 (fruit fly): T236‑p, Akt1 (cow): S124‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cultured cells
Species studied:  rat

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypoxia/reoxygenation increase
SP600125 hypoxia/reoxygenation inhibit treatment-induced increase
V-100 hypoxia/reoxygenation inhibit treatment-induced increase

T450-p - Akt1 (human)
Modsite: tAQMItItPPDQDDs SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T450‑p, Akt1 iso2 (human): T388‑p, Akt1 (mouse): T450‑p, Akt1 (rat): T450‑p, Akt1 (fruit fly): T565‑p, Akt1 (cow): T450‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cultured cells
Species studied:  rat
Downstream Regulation
Effect of modification (function):  activity, induced
Effect of modification (process):  apoptosis, induced
Comments:  reactivation after ischemia

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cultured cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SP600125 decrease
MKK4 (human) increase constitutively active
hypoxia/reoxygenation increase
hypoxia/reoxygenation MKK4 (human) augment treatment-induced increase constitutively active
SP600125 hypoxia/reoxygenation inhibit treatment-induced increase

S124-p - Akt1 (rat)
Modsite: TMDFRSGsPSDNsGA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S124‑p, Akt1 iso2 (human): S62‑p, Akt1 (mouse): S124‑p, Akt1 (rat): S124‑p, Akt1 (fruit fly): T236‑p, Akt1 (cow): S124‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cultured cells
Species studied:  rat

T308-p - Akt1 (rat)
Modsite: KDGATMKtFCGTPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cultured cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypoxia increase
V-150 hypoxia inhibit treatment-induced increase
SP600125 hypoxia inhibit treatment-induced increase
hypoxia/reoxygenation increase
SP600125 hypoxia/reoxygenation inhibit treatment-induced increase
V-100 hypoxia/reoxygenation inhibit treatment-induced increase
ischemia/reperfusion increase
V-150 ischemia/reperfusion inhibit treatment-induced increase

T450-p - Akt1 (rat)
Modsite: TAQMITItPPDQDDS SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T450‑p, Akt1 iso2 (human): T388‑p, Akt1 (mouse): T450‑p, Akt1 (rat): T450‑p, Akt1 (fruit fly): T565‑p, Akt1 (cow): T450‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cultured cells
Species studied:  rat

S473-p - Akt1 (rat)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cultured cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypoxia increase
V-150 hypoxia inhibit treatment-induced increase
SP600125 hypoxia inhibit treatment-induced increase
hypoxia/reoxygenation increase
V-150 hypoxia/reoxygenation inhibit treatment-induced increase
SP600125 hypoxia/reoxygenation inhibit treatment-induced increase
hypoxia/reoxygenation increase
V-100 hypoxia/reoxygenation inhibit treatment-induced increase
VX702 hypoxia/reoxygenation no effect upon treatment-induced increase
SP600125 decrease
MKK4 (human) increase constitutively active
hypoxia/reoxygenation increase
hypoxia/reoxygenation MKK4 (human) augment treatment-induced increase constitutively active
SP600125 hypoxia/reoxygenation inhibit treatment-induced increase
ischemia/reperfusion increase
V-150 ischemia/reperfusion inhibit treatment-induced increase

S9-p - GSK3B (rat)
Modsite: SGRPRTTsFAESCKP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cultured cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypoxia/reoxygenation increase
V-150 hypoxia/reoxygenation inhibit treatment-induced increase
SP600125 hypoxia/reoxygenation inhibit treatment-induced increase

S63-p - Jun (rat)
Modsite: KNSDLLtsPDVGLLK SwissProt Entrez-Gene
Orthologous residues
Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p, Jun (cow): S63‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cultured cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypoxia increase
V-150 hypoxia inhibit treatment-induced increase
SP600125 hypoxia inhibit treatment-induced increase
hypoxia/reoxygenation increase
V-150 hypoxia/reoxygenation inhibit treatment-induced increase
SP600125 hypoxia/reoxygenation inhibit treatment-induced increase
hypoxia/reoxygenation increase
V-100 hypoxia/reoxygenation inhibit treatment-induced increase
VX702 hypoxia/reoxygenation no effect upon treatment-induced increase

T208-p - MAPKAPK2 (rat)
Modsite: TSHNSLTtPCYTPYY SwissProt Entrez-Gene
Orthologous residues
MAPKAPK2 (human): T222‑p, MAPKAPK2 iso2 (human): T222‑p, MAPKAPK2 (mouse): T208‑p, MAPKAPK2 (rat): T208‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  myocyte-heart
Cellular systems studied:  primary cultured cells
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ischemia/reperfusion increase
V-150 ischemia/reperfusion inhibit treatment-induced increase
ischemia increase
VX702 ischemia inhibit treatment-induced increase